WHO Pandemic Treaty: Navigating the Ethical Divide between IP Rights and Global Health Equity

The ongoing negotiations for the World Health Organization (WHO) Pandemic Treaty have reached a critical juncture, revealing a deep-seated ethical and structural divide between the Global North and the Global South. Initiated in the wake of the COVID-19 pandemic, the treaty aims to establish a legally binding framework for global pandemic preparedness and response. However, the 'ethical deadlock' centers on two primary pillars: the Pathogen Access and Benefit-Sharing (PABS) system and the protection of Intellectual Property Rights (IPR).

Developed nations, home to major pharmaceutical giants, argue that stringent IPR protections are essential to foster innovation and ensure the rapid development of vaccines and treatments. Conversely, developing nations, led by voices like India and the Africa Group, contend that the current global health architecture is inherently inequitable. They highlight the 'vaccine apartheid' witnessed during COVID-19, where life-saving medical countermeasures were hoarded by wealthy nations while the Global South struggled for access.

A significant point of contention is the PABS system. Developing countries are often the primary sources of pathogen samples and genetic sequence data. While they share this data globally to facilitate research, they frequently find themselves excluded from the benefits—namely, the vaccines and diagnostics derived from that data. India has consistently advocated for a treaty that ensures 'equitable access' to medical products, technology transfer, and the scaling up of local manufacturing capacities in developing regions.

From an ethical perspective, this debate reflects the tension between 'National Interest' and 'Global Common Good.' It raises fundamental questions about the 'Ethics of International Relations': Should the profit motives and property rights of corporations take precedence over the universal right to health? The resolution of this deadlock will determine whether future global health governance is based on charity or on a justice-based framework of mutual accountability.